Legal News

Coronavirus (COVID-19)—EMA begins evaluation of Moderna booster dose

Published on: 29 September 2021
Published by LNB News

LNB News 29/09/2021

Document Information

Issue Date: 29 September 2021

Published Date: 29 September 2021

Jurisdiction(s): European Union

Article summary

The European Medicines Agency (EMA) has begun to evaluate an application for Spikevax, the coronavirus (COVID-19) vaccine made by Moderna, to be given as a booster jab to people six months after being fully vaccinated. The scope of Moderna’s application is for its Spikevax vaccine to be given as a booster to all fully vaccinated people aged 12 and above so that it improves protection after it has waned. The application follows the EMA and European Centre for Disease Prevention and Control's (ECDC) previous statement that booster jabs should be considered for people with weakened immune systems.

Popular documents